Clinical outcomes

At Optegra we are committed to providing individually tailored eye care solutions with the aim of delivering the best possible outcome for you. We ensure these standards are met by continually monitoring and measuring every patient’s results during their follow up visits, benchmarking these to standards where possible. We then publish this information on our website and in patient literature to allow you to make an informed decision when choosing an eye care provider.

How do we measure outcomes?

Visual outcomes after Clarivu treatment can be reported as the proportion of patients achieving the following standards using both eyes together, without glasses:

• 6/12 distance vision
• N8 near vision

To put this into perspective, to drive a car in the UK you must be able to meet the minimum eyesight standard for driving by having a visual acuity of at least 6/12 (with glasses or contact lenses if necessary) using both eyes together.*

In the UK we often use a reading chart to measure vision close up. ‘N8’ vision is what would normally be required for comfortable reading of newspapers.

*Other factors are involved and more details can be found on www.gov.uk/driving-eyesight-rules.

If required, patients who feel they desire even further freedom from spectacles, may be offered an enhancement with laser vision correction at Optegra at no additional charge. This, of course, will depend on the circumstances of each individual case and this option will be discussed carefully with the treating surgeon.

Patient satisfaction results

To ensure we provide our patients with the best possible experience we invite them to complete our online Patient Satisfaction Survey. The results are used to help us ensure we uphold our promise to provide a premium, expert service at all times throughout the patient journey. View the results here.

The outcomes sample data explained:

• Multi-surgeon, multi-site evaluation of Multifocal lens implant (Clarivu) outcomes.
• Treatments took place between 1 July 2012 and 31 Dec 2016 at one of seven Optegra hospitals in the UK.
• Follow-up visits took place between 25 July 2012 and 22 February 2017.
• Sample of 6,374 eyes of 3,187 patients.
• All patients included underwent bilateral, sequential Multifocal lens implant treatment. Patients who were not capable of achieving 6/6 vision in either eye, for instance due to amblyopia (“lazy eye”), were excluded.
• Results refer to primary treatments only, before any enhancement procedures.
• Results are as recorded at the last follow-up visit.